• Something wrong with this record ?

Quantification of uPA in breast tumour tissue extracts by microarray immunoassay: Comparison with ELISA technology

Liu Shi, Thomas Gehin, Yann Chevolot, William Jacot, Pierre-Jean Lamy, Emmanuelle Laurenceau

. 2018 ; 16 (3) : 214-220.

Language English Country Czech Republic

Document type Research Support, Non-U.S. Gov't, Comparative Study

Persistent link   https://www.medvik.cz/link/bmc18039976

The urokinase-type plasminogen activator (uPA) and PA inhibitor 1 (PAI-1) play important roles in breast cancer metastasis through cell migration and invasion. They are clinically applicable prognostic and predictive markers. High levels of uPA and PAI-1 are associated with high risk of recurrence and adjuvant chemotherapy provides substantial benefit for this breast cancer population. The current sole validated method for quantifying uPA level in breast tumour tissue is ELISA assay. It requires 50–300 mg of fresh or frozen tissue, which is the main limitation for routine use. In this study, we evaluated the performances of customized antibody microarray to quantify uPA concentration from reduced extraction solution of breast tumour tissue and compared it with standard ELISA kit. We firstly optimized the elaboration of customized antibody microarray in order to sensitively detect and quantify uPA standard solutions. In the best conditions, we analysed uPA concentration in 16 cytosolic extracts from breast tumour tissue. Results showed that our customized antibody microarray could correctly quantify uPA concentration while consuming 100 times less volume of tumour tissue extraction solution than ELISA. Our antibody microarray is a powerful and promising tool for the miniaturization of the immunoassay quantification of uPA from breast tumour tissue extracts.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc18039976
003      
CZ-PrNML
005      
20190305064115.0
007      
ta
008      
181211s2018 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jab.2018.01.001 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Shi, Liu $u Lyon University, Lyon Institute of Nanotechnology INL-UMR5270, CNRS, Ecole Centrale de Lyon, Ecully, France
245    10
$a Quantification of uPA in breast tumour tissue extracts by microarray immunoassay: Comparison with ELISA technology / $c Liu Shi, Thomas Gehin, Yann Chevolot, William Jacot, Pierre-Jean Lamy, Emmanuelle Laurenceau
504    __
$a Literatura
520    9_
$a The urokinase-type plasminogen activator (uPA) and PA inhibitor 1 (PAI-1) play important roles in breast cancer metastasis through cell migration and invasion. They are clinically applicable prognostic and predictive markers. High levels of uPA and PAI-1 are associated with high risk of recurrence and adjuvant chemotherapy provides substantial benefit for this breast cancer population. The current sole validated method for quantifying uPA level in breast tumour tissue is ELISA assay. It requires 50–300 mg of fresh or frozen tissue, which is the main limitation for routine use. In this study, we evaluated the performances of customized antibody microarray to quantify uPA concentration from reduced extraction solution of breast tumour tissue and compared it with standard ELISA kit. We firstly optimized the elaboration of customized antibody microarray in order to sensitively detect and quantify uPA standard solutions. In the best conditions, we analysed uPA concentration in 16 cytosolic extracts from breast tumour tissue. Results showed that our customized antibody microarray could correctly quantify uPA concentration while consuming 100 times less volume of tumour tissue extraction solution than ELISA. Our antibody microarray is a powerful and promising tool for the miniaturization of the immunoassay quantification of uPA from breast tumour tissue extracts.
650    12
$a nádory prsu $x diagnóza $x imunologie $7 D001943
650    12
$a aktivátor plasminogenu urokinasového typu $x analýza $x imunologie $x škodlivé účinky $7 D014568
650    12
$a čipová analýza tkání $x metody $x přístrojové vybavení $7 D046888
650    _2
$a ELISA $7 D004797
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a biologické markery $7 D015415
650    _2
$a prognóza $7 D011379
650    _2
$a imunoanalýza $x metody $7 D007118
650    _2
$a lidé $7 D006801
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Gehin, Thomas $u Lyon University, Lyon Institute of Nanotechnology INL-UMR5270, CNRS, Ecole Centrale de Lyon, Ecully, France
700    1_
$a Chevolot, Yann $u Lyon University, Lyon Institute of Nanotechnology INL-UMR5270, CNRS, Ecole Centrale de Lyon, Ecully, France
700    1_
$a Jacot, William $u Montpellier Cancer Institute Val d'Aurelle, Medical Oncoly Department, Montpellier, FrancecInstitut Médical d'Analyse Génomique-Labosud, Montpellier, France
700    1_
$a Lamy, Pierre-Jean $u Institut Médical d'Analyse Génomique-Labosud, Montpellier, France; Montpellier Cancer Institute Val d'Aurelle, Translational research unit and Biological Ressources Center, Montpellier, France
700    1_
$a Laurenceau, Emmanuelle $u Lyon University, Lyon Institute of Nanotechnology INL-UMR5270, CNRS, Ecole Centrale de Lyon, Ecully, France
773    0_
$t Journal of applied biomedicine $x 1214-021X $g Roč. 16, č. 3 (2018), s. 214-220 $w MED00012667
856    41
$u https://jab.zsf.jcu.cz/pdfs/jab/2018/03/09.pdf $y plný text volně přístupný
910    __
$a ABA008 $b B 2301 $c 1249 $y 4 $z 0
990    __
$a 20181211090250 $b ABA008
991    __
$a 20190305064429 $b ABA008
999    __
$a ok $b bmc $g 1358050 $s 1037039
BAS    __
$a 3
BMC    __
$a 2018 $b 16 $c 3 $d 214-220 $i 1214-021X $m Journal of Applied Biomedicine $x MED00012667
LZP    __
$c NLK185 $d 20190305 $a NLK 2018-52/dk

Find record

Citation metrics

    Archiving options